RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Abionyx Pharma - Stock

Abionyx Pharma EBIT 2024

Abionyx Pharma EBIT

-6.43 M EUR

Ticker

ABNX.PA

ISIN

FR0012616852

WKN

A14QR9

In 2024, Abionyx Pharma's EBIT was -6.43 M EUR, a 88.34% increase from the -3.41 M EUR EBIT recorded in the previous year.

The Abionyx Pharma EBIT history

YEAREBIT (undefined EUR)
2026e2.74
2025e-9.18
2024e-6.43
2023-3.41
2022-4.11
2021-5.95
2020-2.97
2019-2.53
2018-7.05
2017-6.64
2016-24.04
2015-15.47
2014-6.07
2013-9.81

Abionyx Pharma Aktienanalyse

What does Abionyx Pharma do?

Abionyx Pharma SA is a biotechnology company based in France that specializes in the development and commercialization of innovative therapeutic approaches for rare diseases. The company was founded in 2000 by a group of scientists and pharmaceutical experts and has since become a leading company in the industry. The business model of Abionyx Pharma is based on the discovery and development of drugs for rare diseases. The company focuses in particular on diseases for which there are still no or only inadequate therapies. With this focus, Abionyx Pharma takes advantage of orphan drug designations and other incentive programs offered by governments and authorities around the world. These programs are intended to provide incentives for the research and development of drugs for rare diseases. Abionyx Pharma has a wide range of products in various stages of development. These include therapeutics for musculoskeletal diseases, neural disorders, and chronic inflammation. The company also has a portfolio of compounds and drugs that can be used as a platform for the development of drugs for other diseases. One of Abionyx Pharma's key products is ONO-8455, a treatment package for osteoarthritis. This is a common joint disease caused by progressive cartilage wear. ONO-8455 has the potential to be a very important therapy option for the disease and could potentially become a blockbuster drug. Another important product from Abionyx Pharma is ABX464. This is a topical therapy for the treatment of hemorrhoid inflammation. ABX464 has been tested in clinical trials and has shown promising results in terms of its effectiveness in treating hemorrhoids. Abionyx Pharma also has other projects in the pipeline, including a therapy for Fabry disease. Fabry disease is a very rare genetic disorder that affects the metabolism of lipids and other important molecules in the body. Abionyx Pharma is developing a therapy based on a novel technology that acts through DNA methylation. To achieve its business goals, Abionyx Pharma works closely with scientific and clinical partners. It also forms strategic alliances with other pharmaceutical companies to market its products globally and gain a significant market share. Overall, Abionyx Pharma is an attractive company for investors looking for a biotechnology company specializing in the development and commercialization of drugs for rare diseases. The company has a strong portfolio of products in various stages of development and has already presented promising results. With its close collaboration with partners and strategic alliances, it is able to market its products globally and remain a strong competitor in the industry. Abionyx Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Abionyx Pharma's EBIT

Abionyx Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Abionyx Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Abionyx Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Abionyx Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Abionyx Pharma Stock

How much did Abionyx Pharma achieve in EBIT for the current year?

In the current year, Abionyx Pharma has achieved an EBIT of -6.43 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Abionyx Pharma.

How has the EBIT of Abionyx Pharma developed in recent years?

The EBIT of Abionyx Pharma has increased by 88.335% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Abionyx Pharma?

The EBIT of Abionyx Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Abionyx Pharma pay?

Over the past 12 months, Abionyx Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abionyx Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Abionyx Pharma?

The current dividend yield of Abionyx Pharma is .

When does Abionyx Pharma pay dividends?

Abionyx Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abionyx Pharma?

Abionyx Pharma paid dividends every year for the past 0 years.

What is the dividend of Abionyx Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abionyx Pharma located?

Abionyx Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abionyx Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abionyx Pharma from 6/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.

When did Abionyx Pharma pay the last dividend?

The last dividend was paid out on 6/13/2024.

What was the dividend of Abionyx Pharma in the year 2023?

In the year 2023, Abionyx Pharma distributed 0 EUR as dividends.

In which currency does Abionyx Pharma pay out the dividend?

The dividends of Abionyx Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abionyx Pharma

Our stock analysis for Abionyx Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abionyx Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.